Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome

This is the authors' abstract. We don't add key points for this paper.

Transient abnormal myelopoiesis (TAM), also known as transient leukemia or transient myeloproliferative disorder, occurs in approximately 5–10% of neonates with Down syndrome (DS) and is characterized by the transient appearance of blast cells with megakaryoblastic and/or erythroblastic characteristics in the peripheral blood [ 1 , 2 ]. Approximately 20% of TAM cases result in early death and 16–23% of survivors develop acute megakaryoblastic leukemia (AMKL) within 4 years [ 3 , 4 , 5 , 6 ]. A somatic GATA1 gene mutation is shared by both TAM [ 7 ] and AMKL cells [ 8 , 9 ].